It’s the moment of truth and it’s your move to decide the most optimal treatment for your patient with advanced metastatic melanoma. Participate in this DecisionSim™, step-by-step, simulation-based learning module rooted in the concept of clinical decision assessment to assess your own skills in treatment decision-making, enhanced with personalized coaching from Dr. Jeffrey S. Weber.
Are you a top doc in treating metastatic melanoma? Hone your skills in implementing a treatment plan for a patient with advanced metastatic melanoma.
Available credits: 0.25
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Jeffrey S. Weber, MD, PhD
Laura and Isaac Perlmutter Cancer Center
New York, NY
Patent Holder: Named a PD-1 biomarker patent by Biodesix and on a CTLA-4 biomarker patent by Moffitt
Consulting Fees: Astra Zeneca, BMS, Celldex, CytomX, GSK, Incyte, Merck, Novartis, Pfizer, Regeneron
Contracted Research: NextCure
Stocks: CytpmX, Biond, Protean
- Ann Early has nothing to disclose.
- Jessica Kimball has nothing to disclose.
- Nick Lombardi has disclosed ownership interest: Vertex Pharmaceuticals.
- Brian P. McDonough MD, FAAFP has nothing to disclose.
- William Mencia, MD, FACEHP, CHCP has nothing to disclose.
- Tricia O’Leary has nothing to disclose.
- The PIM planners and managers have nothng to disclose.
The goal of this activity is to inform and guide clinicians on decisions regarding appropriate first-line treatment regimens for patients with advanced metastatic melanoma.
Discuss unmet needs in the staging and first-line treatment of advanced melanoma and the utility of updated recommendations.
Identify key clinical trial data on immunotherapies and their combinations that have been associated with improved outcomes for patients with advanced melanoma.
Provide appropriate first-line treatment regimens for patients with advanced metastatic melanoma.
This activity is designed to meet the educational needs of oncologists, dermatologists, pharmacists, registered nurses, and pathologists.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Postgraduate Institute for Medicine (PIM). GLC is accredited by the ACCME to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Learning Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-2553-H01)
Type of Activity: Knowledge
Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Continuing Nursing Education
The maximum number of hours awarded this Continuing Nursing Education activity is 0.25 contact hours.
Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Jointly provided by Postgraduate Institute for Medicine and Prova Education.
This activity is supported by independent educational grants from Bristol Myers Squibb and Merck.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.